Zacks Investment Research cut shares of Caladrius Biosciences (NASDAQ:CLBS) from a hold rating to a sell rating in a report published on Wednesday.
According to Zacks, “Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York. “
Separately, HC Wainwright restated a buy rating and set a $7.00 price target on shares of Caladrius Biosciences in a research report on Friday, November 10th.
Caladrius Biosciences (NASDAQ:CLBS) last posted its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.41. analysts predict that Caladrius Biosciences will post -2.54 earnings per share for the current year.
A hedge fund recently raised its stake in Caladrius Biosciences stock. Vanguard Group Inc. raised its position in Caladrius Biosciences Inc (NASDAQ:CLBS) by 2.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 155,380 shares of the biotechnology company’s stock after purchasing an additional 4,163 shares during the quarter. Vanguard Group Inc.’s holdings in Caladrius Biosciences were worth $723,000 as of its most recent SEC filing. 6.41% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Caladrius Biosciences (CLBS) Rating Lowered to Sell at Zacks Investment Research” was posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.themarketsdaily.com/2018/01/14/caladrius-biosciences-clbs-rating-lowered-to-sell-at-zacks-investment-research.html.
About Caladrius Biosciences
Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.